Ann: VitroGro Sales Planned to Start in June 2012, page-45

re: Ann: VitroGro Sales Planned to Start in J... Some very harsh critics among holders on here. ASH is spot on, management have performed their duty to TIS stakeholders with distinction imo, and deserve far more credit. Increasing the true underlying fundamental value of a company's securities is what it's all about, and this is exactly what they've done - Let the market continue snoozing... they'll see the bigger picture before much longer.

TIS time to shine - $75m MCap... Goodbye...

Clinical data from difficult-to-treat venous ulcer patients treated with VitroGro® ECM for 12 weeks show:

* 34% were completely healed.
* 43% were more than 90% healed.
* 82% were improved ie. were partially or completely healed.
* Average reduction in venous ulcer area was 56%.
* Average ulcer size at the start of the trial was 7.2 cm2.
* Average time the treated ulcers had not responded to expert care prior to VitroGro® ECM treatment was 36 months.
* Average age of the patients in this study was 74 years.
* Treatment twice per week was no more effective than once per week.
* No adverse events related to VitroGro® ECM have been reported after a total of more than 750 uses of the VitroGro® ECM device.
* Expert health economics modelling indicates that VitroGro® ECM offers the opportunity for more cost effective treatment of wounds than the current standard of care.
___

"The multi-centre study of VitroGro® found 82 per cent of the patients taking part in the trial were partially or completely healed in 12 weeks."

"The average treatment time that patients' venous ulcers had not responded to expert care before VitroGro® treatment was 36 months."

"There's nothing else like it in the market in terms of approach, outcome or cost effectiveness."

"Nurses have also been impressed by the visible and consistent performance of VitroGro®, particularly the visible and quick improvement seen in challenging cases combined with ease of use and pain reduction."

"We're very excited by these results as it's a new formulation, which is going to be extremely cost effective to the consumer," said Professor Zee Upton from QUT's Institute of Health and Biomedical Innovation"
___

Keith Harding

Professor Keith Harding is the Director of the Wound Healing Research Unit and Professor of Rehabilitation Medicine at Cardiff University in Wales and is widely acknowledged as the foremost international researcher / clinician into wound healing, with particular emphasis on chronic wounds. He is an Advisor to the Board of Tissue Therapies and is overseeing the current EU venous ulcer human trial of VitroGro®.

Q: You must get many requests to trial or endorse new treatments. What made you take VitroGro seriously and get involved more closely with its development?

Keith Harding: "The problem with wound healing is that it has been around for many, many centuries. There have been many attempts over recent years to come up with solutions to the problem of non-healing wounds.

Unfortunately many of the early attempts at novel and new therapies for this particular problem have suffered from a lack of good basic science to underpin the product and many of those products have arrived and failed.

The one thing that I have found impressive in working with Tissue Therapies is that they seem to have commitment to understanding the science and managing the development of the product in a structured way that doesn’t go anywhere unless the science is there to support the data."

Q: So what is your perspective on the VitroGro trials?

Keith Harding: "I have been around this subject for nearly 30 years. I have seen a lot of new products come and go. The one thing that was impressive both from the preclinical data and the early clinical studies is that in the clinical studies particularly, there seemed to be a greater consistency of response in the patients that were exposed to this product, far more consistent than I’ve seen with other biological therapies that I personally have been involved in trialling or evidence that I have reviewed in other capacities."

Q: Keith, Tissue Therapies is a very small company in comparison with well known pharmaceutical giants, what will its next steps need to be if VitroGro fulfills its early promise and where do you see the company’s future?

Keith Harding: "Although Tissue Therapies is a small company compared to many of the larger players in this area, the one thing that is impressive is that Tissue Therapies seem to have a genuine interest, focus and passion in trying to provide a sound basis and evaluation of the product that they have. My hope - and I’m not a spokesperson for Tissue Therapies - is that they will continue that focus, they will continue that passion, and I would anticipate that the success of VitroGro will be significant, but I would also hope that it will be the first generation of a series of biologically based therapies that may be developed by this company as it goes forward, and I would expect that because of the complexity of the customer base that the company will have to deal with, is that they would probably be talking to major companies and developing a partnership arrangement so they will have enough bodies on the ground, enough sales staff to go out and provide the education and training for clinicians who may be seeing patients with wounds."

Keith Harding Interview
___

Why customers choose Quintiles for commercial solutions

Identify value: Quintiles draws on experience and data in stakeholder assessment, sales and marketing, which helps us to identify outcome and pricing requirements
to demonstrate unique value. We create commercial solutions that consistently achieve quality results.

* To help support your brand’s commercial initiatives, Quintiles has developed strong relationships with key gatekeepers in local markets worldwide, including opinion leaders, physicians and patients

* To help shape your strategies, Quintiles has more than 300 medical doctors and approximately 400 PhDs on staff, working in all major therapeutic areas

Promote value: Quintiles has managed hundreds of sales teams in primary and specialty care in 30+ countries. Drawing on three decades of experience, market insights, and outcomes research, we help create the best product profiles, then plan and create multi-channel campaigns to deliver the right value messages to the right stakeholders at the right time. The results are impressive.

* We’ve helped launch 30 of the world’s top-selling drugs. We’ve helped market 21 of the top 30 best-selling oncology products in 2008 and more than half of the “breakthrough” products introduced in the last 12 years

Quintiles - navigating the new health